{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T19:13:03Z","timestamp":1761765183227},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2009,8,7]],"date-time":"2009-08-07T00:00:00Z","timestamp":1249603200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"published-print":{"date-parts":[[2010,9]]},"DOI":"10.1007\/s12032-009-9284-y","type":"journal-article","created":{"date-parts":[[2009,8,6]],"date-time":"2009-08-06T12:06:10Z","timestamp":1249560370000},"page":"768-773","source":"Crossref","is-referenced-by-count":45,"title":["Imatinib mesylate-induced acute liver failure in a patient with gastrointestinal stromal tumors"],"prefix":"10.1007","volume":"27","author":[{"given":"Onder","family":"Tonyali","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ugur","family":"Coskun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramazan","family":"Yildiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tarkan","family":"Karakan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Umut","family":"Demirci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nalan","family":"Akyurek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mustafa","family":"Benekli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suleyman","family":"Buyukberber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,8,7]]},"reference":[{"key":"9284_CR1","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","volume":"348","author":"SG O\u2019Brien","year":"2003","unstructured":"O\u2019Brien SG, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348:994\u20131004.","journal-title":"N Engl J Med"},{"key":"9284_CR2","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1056\/NEJMoa020461","volume":"347","author":"GD Demetri","year":"2002","unstructured":"Demetri GD, et al. Efficacy and safety of imatinib mesylate in advanced gastro-intestinal stromal tumors. N Engl J Med. 2002;347:472\u201380.","journal-title":"N Engl J Med"},{"key":"9284_CR3","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","volume":"344","author":"BJ Druker","year":"2001","unstructured":"Druker BJ, et al. Efficacy and safety of a specific inhibitor of the BCRABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344:1031\u20137.","journal-title":"N Engl J Med"},{"key":"9284_CR4","first-page":"935","volume":"8","author":"MH Cohen","year":"2002","unstructured":"Cohen MH, et al. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin Cancer Res. 2002;8:935\u201342.","journal-title":"Clin Cancer Res"},{"key":"9284_CR5","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1157\/13111687","volume":"30","author":"F Fuster","year":"2007","unstructured":"Fuster F, Medina L, Vallansot R, Granell M, Brugeuera M. Imatinib induced toxic hepatitis: description of two cases and review of the literature. Gastroenterol Hepatol. 2007;30:525\u201330.","journal-title":"Gastroenterol Hepatol"},{"key":"9284_CR6","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1182\/blood.V99.6.1928","volume":"99","author":"M Talpaz","year":"2002","unstructured":"Talpaz M, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood. 2002;99:1928\u201337.","journal-title":"Blood"},{"key":"9284_CR7","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/ajh.20486","volume":"81","author":"TJ Cross","year":"2006","unstructured":"Cross TJ, Bagot C, Portmann B, Wendon J, Gillett D. Imatinib mesylate as a cause of acute liver failure. Am J Hematol. 2006;81:189\u201392.","journal-title":"Am J Hematol"},{"key":"9284_CR8","doi-asserted-by":"crossref","first-page":"3455","DOI":"10.1182\/blood-2003-07-2323","volume":"102","author":"NU Lin","year":"2003","unstructured":"Lin NU, et al. Fatal hepatic necrosis following Imatinib mesylate therapy. Blood. 2003;102:3455\u20136.","journal-title":"Blood"},{"key":"9284_CR9","doi-asserted-by":"crossref","first-page":"6608","DOI":"10.3748\/wjg.v13.i48.6608","volume":"13","author":"E Ridruejo","year":"2007","unstructured":"Ridruejo E, et al. Imatinib-induced fatal acute liver failure. World J Gastroenterol. 2007;13:6608\u201311.","journal-title":"World J Gastroenterol"},{"key":"9284_CR10","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1080\/14639230500236818","volume":"47","author":"K Ikeda","year":"2006","unstructured":"Ikeda K, et al. Fatal hepatitis B virus reactivation in a chronic myeloid leukemia patient during imatinib mesylate treatment. Leuk Lymphoma. 2006;47:155\u20137.","journal-title":"Leuk Lymphoma"},{"key":"9284_CR11","first-page":"e86","volume":"49","author":"TJ Thia","year":"2008","unstructured":"Thia TJ, Tan HH, Chuah TH, Chow WC, Lui HF. Imatinib mesylate-related fatal acute hepatic failure in a patient with chronic myeloid leukaemia and chronic hepatitis B infection. Singapore Med J. 2008;49:e86\u20139.","journal-title":"Singapore Med J"},{"key":"9284_CR12","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1038\/sj.leu.2402702","volume":"16","author":"K Ohyashiki","year":"2002","unstructured":"Ohyashiki K, et al. Imatinib mesylate-induced hepato-toxicity in chronic myeloid leukemia demonstrated focal necrosis resembling acute viral hepatitis. Leukemia. 2002;16:2160\u20131.","journal-title":"Leukemia"},{"key":"9284_CR13","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1038\/sj.leu.2402910","volume":"17","author":"C James","year":"2003","unstructured":"James C, Trouette H, Marit G, Cony-Makhoul P, Mahon FX. Histological features of acute hepatitis after imatinib mesylate treatment. Leukemia. 2003;17:978\u20139.","journal-title":"Leukemia"},{"key":"9284_CR14","first-page":"75","volume":"39","author":"WS Ayoub","year":"2005","unstructured":"Ayoub WS, et al. Imatinib (Gleevec)-induced hepatotoxicity. J Clin Gastroenterol. 2005;39:75\u20137.","journal-title":"J Clin Gastroenterol"},{"key":"9284_CR15","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1080\/10428190412331272721","volume":"45","author":"S Kikuchi","year":"2004","unstructured":"Kikuchi S, et al. Severe hepatitis and complete molecular response caused by imatinib mesylate: possible association of its serum concentration with clinical outcomes. Leuk Lymphoma. 2004;45:2349\u201351.","journal-title":"Leuk Lymphoma"},{"key":"9284_CR16","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1007\/s10620-006-9117-1","volume":"52","author":"AL Mindikoglu","year":"2007","unstructured":"Mindikoglu AL, et al. Imatinib mesylate (glevec) hepatotoxicity. Dig Dis Sci. 2007;52:598\u2013601.","journal-title":"Dig Dis Sci"},{"key":"9284_CR17","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1080\/10245330600937929","volume":"12","author":"E Al Sobhi","year":"2007","unstructured":"Al Sobhi E, Zahrani Z, Zevallos E, Zuraiki A. Imatinib-induced immune hepatitis: case report and literature review. Hematology. 2007;12:49\u201353.","journal-title":"Hematology"},{"key":"9284_CR18","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1097\/01.meg.0000216941.42306.0e","volume":"18","author":"A Pariente","year":"2006","unstructured":"Pariente A, et al. Imatinib mesylate-induced acute hepatitis in a patient treated for gastrointestinal stromal tumour. Eur J Gastroenterol Hepatol. 2006;18:785\u20137.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"9284_CR19","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1159\/000111092","volume":"118","author":"JH Kong","year":"2007","unstructured":"Kong JH, et al. Early imatinib-mesylate-induced hepatotoxicity in chronic myelogenous leukaemia. Acta Haematol. 2007;118:205\u20138.","journal-title":"Acta Haematol"},{"key":"9284_CR20","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1097\/01.meg.0000243867.56454.13","volume":"18","author":"V Dhalluin-Venier","year":"2006","unstructured":"Dhalluin-Venier V, et al. Imatinib mesylate-induced acute hepatitis with autoimmune features. Eur J Gastroenterol Hepatol. 2006;18:1235\u20137.","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"6 Suppl","key":"9284_CR21","first-page":"357","volume":"91","author":"D Ferrero","year":"2006","unstructured":"Ferrero D, et al. Corticosteroids can reverse severe imatinib-induced hepatotoxicity. Haematologica. 2006;91(6 Suppl):357.","journal-title":"Haematologica"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-009-9284-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12032-009-9284-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-009-9284-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T22:22:40Z","timestamp":1559427760000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12032-009-9284-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,8,7]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,9]]}},"alternative-id":["9284"],"URL":"https:\/\/doi.org\/10.1007\/s12032-009-9284-y","relation":{},"ISSN":["1357-0560","1559-131X"],"issn-type":[{"value":"1357-0560","type":"print"},{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,8,7]]}}}